ZICCUM AB Half Year Report Q2 2019
Summary of Half Year Report second quarter 2019: This has been an eventful year for Ziccum.
Summary of Half Year Report, second quarter 2019
2019 has been eventful for Ziccum: We have filed a patent application for an important component in the development of new vaccines, Adenovirus. This has resulted in several industrial players showing new interest in our technology. We also announced that we have entered into a Contract Research agreement with one of these companies, aimed at evaluating LaminarPace ™ in combination with their own project. In the second quarter we also got together groups of leading industrial and academic players to take part in developing dry formulations of many new vaccines and viruses, in the process furthering LaminarPace’s progress towards adapting to large-scale industrial production of biological drugs and vaccines. Consequently we are well on the way to delivering on the targets we set during our share listing – namely carrying out three pilot studies within one year to develop stable, dry vaccines and biological drugs.
Net sales SEK 0 thousand (2) Net sales SEK 0 thousand (192)
Operating profit SEK -2,296 thousand (-573) Operating profit SEK -3,998 thousand (-728)
Earnings per share before and after dilution SEK -0.38 (-0.24)
Net sales SEK 0 thousand (192)
Operating profit SEK -3,998 thousand (-728)
Earnings per share before and after dilution SEK -0.67 (-0.32)
Significant events during the reporting period (Jan-Jun) 2019
Ziccum reported on January 10, 2019 that the company filed a patent application for a dry, temperature-stable formulation of Adenovirus, so meeting WHO requirements for CTC status. The dry formulation ("the powder") generated by Ziccum's technology LaminarPace ™ can be rapidly dissolved back into solution by the addition of sterile water, after which vaccination or treatment can be carried out.
Significant events after the reporting period
- Ziccum will, on behalf of a vaccine development company, carry out a feasibility study on the development of stable vaccines. At this stage, the preliminary study does not entail any financial compensation, but aims to investigate the compatibility of Ziccum's air-drying capability and the vaccine company's new formulation.
- Otherwise, no significant events have occurred after the reporting period
READ THE WHOLE REPORT HERE
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.
This press release has been submitted for publication by the company's CEO at. 08.00 (CET) on August 21, 2018.